Unraveling the mechanism of action of thiazolidinediones.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis.Journal of diabetes research · 2022
   Pooled it
2. The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.BMC infectious diseases · 2010
   Pooled it
3. Rosiglitazone influences adipose tissue distribution without deleterious impact on heart rate variability in coronary heart disease patients with type 2 diabetes.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2016
   Trial
4. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.Acta psychiatrica Scandinavica · 2009
   Trial
5. Adipose tissue macrophages secrete small extracellular vesicles that mediate rosiglitazone-induced insulin sensitization.Nature metabolism · 2024
   Article
6. Antidiabetic Drug Efficacy in Reduction of Mortality during the COVID-19 Pandemic.Medicina (Kaunas, Lithuania) · 2023
   Review
7. The Role of PPARs in Breast Cancer.Cells · 2022
   Review
8. Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes.Stem cells international · 2022
   Review
9. Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?Molecular metabolism · 2021
   Review
10. Global Epidemiology, Health Outcomes, and Treatment Options for Patients With Type 2 Diabetes and Kidney Failure.Frontiers in clinical diabetes and healthcare · 2021
    Review
11. Sclerostin-Neutralizing Antibody Treatment Rescues Negative Effects of Rosiglitazone on Mouse Bone Parameters.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021
    Article
12. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).Journal of diabetes research · 2020
    Review
13. Plasma Cathepsin D Activity Rather Than Levels Correlates With Metabolic Parameters of Type 2 Diabetes in Male Individuals.Frontiers in endocrinology · 2020
    Article
14. Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA).Journal of diabetes research · 2019
    Review
15. Peroxisome proliferator-activated receptor γ (PPARγ) induces the gene expression of integrin αThe Journal of biological chemistry · 2018
    Article
16. Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018
    Review
17. Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold.ACS combinatorial science · 2017
    Article
18. A Review on the Assessment of the Efficacy of Common Treatments in Polycystic Ovarian Syndrome on Prevention of Diabetes Mellitus.Journal of family & reproductive health · 2017
    Review
19. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.Future cardiology · 2017
    Review
20. Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article

Corrections and comments

• Comment on
  Insights into insulin resistance and type 2 diabetes from knockout mouse models.2000
• Comment on
  Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.2000
• Comment on
  Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.2000

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as